Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jaci.2020.09.017 http://scihub22266oqcxt.onion/10.1016/j.jaci.2020.09.017 33002516!7834224!33002516     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33002516&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Allergy+Clin+Immunol 2020 ; 146 (6): 1295-1301 Nephropedia Template TP {{tp|p=33002516|t=2020. Asthma-associated risk for COVID-19 development |pdf=|usr=}}{{33002516}} gab.com Text Asthma-associated risk for COVID-19 development JO: J Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33002516 #FOAvip The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non-type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments. Twit Text FOAVip Asthma-associated risk for COVID-19 development ????J Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33002516 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33002516 #FOAvip English Wikipedia <ref>{{Cite pmid|33002516}}</ref> Asthma-associated risk for COVID-19 development #MMPMID33002516 Skevaki C; Karsonova A; Karaulov A; Xie M; Renz H J Allergy Clin Immunol 2020[Dec]; 146 (6): 1295-1301 PMID33002516show ga The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non-type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments. |*Asthma/epidemiology/immunology/pathology[MESH] |*COVID-19/epidemiology/immunology/pathology[MESH] |Humans[MESH] |Pandemics[MESH]Asthma-associated risk for COVID-19 development (epmc).pdf DeepDyve Pubget Overpricing